Cardiol Therapeutics logo

Cardiol TherapeuticsNASDAQ: CRDL

Profile

Sector:

Healthcare

Country:

Canada

IPO:

15 January 2019

Next earnings report:

21 November 2024

Last dividends:

N/A

Next dividends:

N/A
$142.81 M
-33%vs. 3y high
49%vs. sector
-vs. 3y high
-vs. sector
-2%vs. 3y high
96%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 22:47:42 GMT
$1.75-$0.09(-4.89%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CRDL Latest News

Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy
proactiveinvestors.com18 November 2024 Sentiment: POSITIVE

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced encouraging results from its Phase II MAvERIC-Pilot study, showcasing the sustained efficacy of its anti-inflammatory therapy, CardiolRx, in treating symptomatic recurrent pericarditis. The findings, which were presented at the American Heart Association Scientific Sessions 2024, highlighted marked improvements in pericarditis pain and inflammation, with benefits persisting throughout the 26-week trial.

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
newsfilecorp.com22 October 2024 Sentiment: POSITIVE

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program. Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced plans to expand the MAVERIC clinical development program and advance CardiolRx™ into a late-stage clinical trial ("MAVERIC-2") to evaluate the impact of CardiolRx™ in recurrent pericarditis patients following cessation of interleukin-1 ("IL-1") blocker therapy.

Cardiol Therapeutics raises $15.5M following over-allotment option exercise
proactiveinvestors.com11 October 2024 Sentiment: POSITIVE

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has successfully raised a total of US$15.5 million through a public offering. The company announced that Canaccord Genuity (TSX:CF, LSE:CF) has exercised its over-allotment option in full, purchasing an additional 1,265,625 Class A common shares at $1.60 per share.

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
newsfilecorp.com11 October 2024 Sentiment: POSITIVE

Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share (the "Offering Price") for gross proceeds of US$13.5 million (the "Offering"), Canaccord Genuity has purchased an additional 1,265,625 Common Shares at the Offering Price pursuant to their exercise in full of the over-allotment option (the "Over-Allotment Option"), for additional gross proceeds to the Company of $2,025,000 before deducting the underwriting commissions. After giving effect to the full exercise of the Over-Allotment Option, Cardiol sold 9,703,125 Common Shares under the Offering, for aggregate gross proceeds of US$15,525,000.

Cardiol Therapeutics prices $13.5M public offering
proactiveinvestors.com09 October 2024 Sentiment: POSITIVE

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL), a clinical-stage life sciences company focused on heart disease treatments, announced on Wednesday it is raising US$13.5 million through a public offering of 8,437,500 Class A common shares priced at $1.60 per share. The company said it plans to use the net proceeds from the offering to advance the clinical development of its lead product, CardiolRx, for the treatment of recurrent pericarditis, a condition involving inflammation of the heart's outer lining.

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
newsfilecorp.com09 October 2024 Sentiment: POSITIVE

Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering. The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
newsfilecorp.com08 October 2024 Sentiment: POSITIVE

Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

Cardiol Therapeutics reaches target enrollment for Phase II acute myocarditis trial
proactiveinvestors.com24 September 2024 Sentiment: POSITIVE

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that it has reached its target enrollment of 100 patients in the ARCHER trial, a Phase II randomized, double-blind, placebo-controlled study evaluating CardiolRx for myocardial recovery in patients with acute myocarditis. "We are pleased to have achieved our target patient enrollment in the ARCHER trial, which reflects the commitment and dedication of our clinical collaborators and participating patients," said Andrew Hamer, chief medical officer at Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL).

CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
InvestorPlace14 May 2024 Sentiment: NEUTRAL

Cardiol Therapeutics (NASDAQ: CRDL) recently released its first quarter 2024 results, showing earnings per share of -10 cents.

Cardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditis
Proactive Investors14 May 2024 Sentiment: POSITIVE

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) presented encouraging advancements in its Phase II clinical trial, ARCHER, at the World Congress on Acute Heart Failure 2024. The conference offered an opportunity for Univ. to showcase their research.

  • 1(current)

What type of business is Cardiol Therapeutics?

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

What sector is Cardiol Therapeutics in?

Cardiol Therapeutics is in the Healthcare sector

What industry is Cardiol Therapeutics in?

Cardiol Therapeutics is in the Drug Manufacturers - Specialty & Generic industry

What country is Cardiol Therapeutics from?

Cardiol Therapeutics is headquartered in Canada

When did Cardiol Therapeutics go public?

Cardiol Therapeutics initial public offering (IPO) was on 15 January 2019

What is Cardiol Therapeutics website?

https://www.cardiolrx.com

Is Cardiol Therapeutics in the S&P 500?

No, Cardiol Therapeutics is not included in the S&P 500 index

Is Cardiol Therapeutics in the NASDAQ 100?

No, Cardiol Therapeutics is not included in the NASDAQ 100 index

Is Cardiol Therapeutics in the Dow Jones?

No, Cardiol Therapeutics is not included in the Dow Jones index

When was Cardiol Therapeutics the previous earnings report?

No data

When does Cardiol Therapeutics earnings report?

The next expected earnings date for Cardiol Therapeutics is 21 November 2024